Evommune vs Zenas BioPharma
EVMN and ZBIO side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How EVMN and ZBIO compare
Zenas BioPharma is the larger company, worth 6.0 times as much as Evommune ($1.9B against $313M).
Evommune scores higher on the StockData Score (7 against 1 for Zenas BioPharma), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | EVMN | ZBIO |
|---|---|---|
| Size and price | ||
| Market cap | $313M | $1.9B |
| Share price | $8.62 | $28.70 |
| Change, 1 year | −55.4% | −11.6% |
| Beta (5Y) | 0.92 | 0.40 |
| Employees | 48 | 167 |
| StockData Score | ||
| Total score | 7 (better) | 1 |
| Valuation score | 1 (better) | 0 |
| Growth score | 0 | 0 |
| Performance score | 0 | 0 |
| Health score | 6 (better) | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 31.3× | – |
| P/B | 1.1× (better) | 8.8× |
| FCF yield | −23.9% | −13.0% (better) |
| Profitability | ||
| Operating margin | −1019% | – |
| Net margin | −947% | – |
| FCF margin | −747% | – |
| Return on equity | −142% (better) | −265% |
| Financial health | ||
| Debt / equity | 0.00 | 1.05 (better) |
| Current ratio | 11.68 (better) | 9.42 |
| Altman Z-score | 6.09 (better) | −1.40 |
| Piotroski F-score | 5 (better) | 1 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 95.4% | 94.0% |
| Held by insiders | 51.6% | 36.1% |
| Insider net buying, 12 months | −$2.1M | $11.4M (better) |
| Short interest, % of float | 19.3% | 27.3% |
Go deeper
- EVMN stock overview
- EVMN income statement
- EVMN valuation and score
- ZBIO stock overview
- ZBIO income statement
- ZBIO valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.